You just read:

Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium

News provided by

Nektar Therapeutics

Feb 18, 2017, 19:24 ET